Clinical trials
Peripheral T Cell Lymphoma clinical trials
Below are recruiting peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 244 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06683885RecruitingPhase 1/Phase 2
Targeted drug combo for elderly DLBCL patients
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
Zhengzhou, HenanAges 65 years+ - NCT05931263RecruitingPhase 3
Tested Chi-BEAM vs BEAM before stem cell transplant for lymphoma
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
Nanjing, JiangsuAges 18–65 - NCT06739265RecruitingPhase 1/Phase 2
Golidocitinib plus CHOP for new T-cell lymphoma
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
BeijingAges 18–70 - NCT06855823RecruitingPhase 1/Phase 2
Study of golidocitinib plus pomalidomide for relapsed/refractory PTCL
This trial tests a combination of two drugs, golidocitinib and pomalidomide, for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–80 - NCT07234162RecruitingPhase 3
Study comparing golidocitinib to standard therapy for relapsed T-cell lymphoma
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
Hefei, AnhuiAges 18 years+ - NCT07074457Recruiting
Study of two drugs for CD30+ T-cell lymphoma
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
Suzhou, JiangsuAges 18–75 - NCT07072221Recruiting
Matching drugs trial for relapsed T-cell lymphoma
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
Suzhou, JiangsuAges 18 years+ - NCT06421948RecruitingPhase 1/Phase 2
Linperlisib and chidamide for PTCL
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Zhengzhou, HenanAges 18–80 - NCT05678933Enrolling by invitationPhase 3
Test adding a targeted drug to CHOP for untreated PTCL
This Phase 3 study compares two chemo options—CHOP alone versus CHOP plus AC—for people whose peripheral T-cell lymphoma is the “T-follicular helper” type (PTCL-TFH). The goal is to see which treatment works better for people who have not received lymphoma treatment yet.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT06420089RecruitingPhase 1
CAR T cells for T-cell lymphoma
This trial tests a new CAR T-cell treatment for T-cell lymphoma that has come back or hasn't responded to standard treatments. The treatment is designed to target cancer cells that have a protein called CD5 on their surface.
New York, New YorkAges 18 years+ - NCT05230680RecruitingPhase 1/Phase 2
Azacitidine with CHOP for newly diagnosed TFH nodal T-cell lymphoma
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
SeoulAges 20–85 - NCT06698822RecruitingPhase 2
Tofacitinib cream for early-stage cutaneous T-cell lymphoma
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
Houston, TexasAges 18 years+ - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Glendale, ArizonaAges 18 years+ - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT06890884RecruitingPhase 2
Comparing two drug combos for untreated DLBCL
This trial tests a new drug, zilovertamab vedotin, added to standard chemo, compared with another approved drug combo for people with untreated DLBCL (a type of lymphoma). It aims to see which is more effective.
Mobile, AlabamaAges 18 years+ - NCT06643221RecruitingEarly Phase 1
Exercise as a booster for cell therapy treatments
This trial tests whether exercise and a heart medicine called isoproterenol can help your immune system work better with donor cell therapies. It may show how to make these treatments more effective.
Tucson, ArizonaAges 21–55 - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Birmingham, AlabamaAges 6 months–30 years - NCT07779018RecruitingPhase 2
CAR-T cell therapy after second-line treatment for aggressive B-cell lymphoma
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
BeijingAges 18–85 - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07000617RecruitingPhase 2
A study of drugs plus radiation for early-stage NK/T-cell lymphoma
This trial tests a combination of the drugs dexamethasone, azacitidine, pegaspargase, and tislelizumab along with radiation therapy for people with stage I or II extranodal NK/T-cell lymphoma. The goal is to see if this treatment works well and is safe for patients who have not yet received treatment.
BeijingAges 18 years+ - NCT05294055RecruitingPhase 2
Mecapegfilgrastim to help collect stem cells for transplant
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Hefei, AnhuiAges 18–65
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peripheral t cell lymphoma?
- Yes. Clin2 currently lists 244 recruiting peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.